Once-daily darunavir/ritonavir and abacavir/lamivudine versus tenofovir/emtricitabine for treatment-naive patients with a baseline viral load of more than 100 000 copies/ml

被引：6
|
作者：
Nishijima, Takeshi [1 ,2 ]
Komatsu, Hirokazu [3 ]
Teruya, Katsuji [1 ]
Tanuma, Junko [1 ]
Tsukada, Kunihisa [1 ]
Gatanaga, Hiroyuki [1 ,2 ]
Kikuchi, Yoshimi [1 ]
Oka, Shinichi [1 ,2 ]
机构：
[1] Natl Ctr Global Hlth & Med, AIDS Clin Ctr, Tokyo 1620052, Japan
[2] Kumamoto Univ, Ctr AIDS Res, Kumamoto, Japan
[3] Saku Cent Hosp, Dept Community Care, Nagano, Japan
来源：
AIDS | 2013年 / 27卷 / 05期
关键词：
TENOFOVIR DISOPROXIL FUMARATE; HIV-INFECTED PATIENTS; DARUNAVIR-RITONAVIR; ABACAVIR-LAMIVUDINE; RENAL SAFETY; EFFICACY; EMTRICITABINE; THERAPY; TRIALS;
D O I：
10.1097/QAD.0b013e32835cadb7
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
The efficacy and safety of fixed-dose abacavir/lamivudine against tenofovir/emtricitabine, both with once-daily darunavir/ritonavir, was examined in 80 treatment-naive patients with a baseline HIV-1 viral load of more than 100 000 copies/ml. The time to virologic failure by 48 weeks was not different between the two groups. The percentage of patients with viral suppression was not significantly different with per protocol population. Tenofovir/emtricitabine showed better tolerability; more patients on abacavir/lamivudine changed regimen than those on tenofovir/emtricitabine. A randomized trial to elucidate the efficacy and safety of these two regimens is warranted.
引用
收藏
页码：839 / 842
页数：4
相关论文
共 28 条
  • [21] Randomized Comparison of Renal Effects, Efficacy, and Safety With Once-Daily Abacavir/Lamivudine Versus Tenofovir/Emtricitabine, Administered With Efavirenz, in Antiretroviral-Naive, HIV-1-Infected Adults: 48-Week Results From the ASSERT Study
    Post, Frank A.
    Moyle, Graeme J.
    Stellbrink, Hans Juergen
    Domingo, Pere
    Podzamczer, Daniel
    Fisher, Martin
    Norden, Anthony G.
    Cavassini, Matthias
    Rieger, Armin
    Khuong-Josses, Marie-Aude
    Branco, Teresa
    Pearce, Helen C.
    Givens, Naomi
    Vavro, Cindy
    Lim, Michael L.
    JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2010, 55 (01) : 49 - 57
  • [22] Non-inferior efficacy for darunavir/ritonavir 400/100 mg once daily versus lopinavir/ritonavir, for patients with HIV RNA below 50 copies/mL in South Africa: The 48-week WRHI 052 study
    Venter, F.
    Moorhouse, M.
    Sokhela, S.
    Maharaj, E.
    Akpomiemie, G.
    Simmons, B.
    Serenata, C.
    Hill, A.
    JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2018, 21 : 156 - 157
  • [23] USE OF ONCE-DAILY DARUNAVIR/R (800/100MG) IN TREATMENT-NAIVE PATIENTS CO-INFECTED WITH HEPATITIS B AND/OR C. DATA FROM THE ARTEMIS STUDY
    Termini, R.
    Lazzarin, A.
    Orani, A.
    Abeele, C. Vanden
    Lavreys, L.
    INFECTION, 2009, 37 : 48 - 49
  • [24] Week 96 resistance analysis of the pooled ECHO and THRIVE Truvada subset in treatment-naive HIV-infected adults with ≤100,000 c/mL baseline viral load
    White, K.
    Van Eygen, V.
    Vingerhoets, J.
    Boven, K.
    Picchio, G.
    Quercia, R.
    Chuck, S.
    Rimsky, L.
    HIV MEDICINE, 2012, 13 : 69 - 69
  • [25] Once-daily dolutegravir versus darunavir plus ritonavir for treatment-naive adults with HIV-1 infection (FLAMINGO): 96 week results from a randomised, open-label, phase 3b study
    Molina, Jean-Michel
    Clotet, Bonaventura
    van Lunzen, Jan
    Lazzarin, Adriano
    Cavassini, Matthias
    Henry, Keith
    Kulagin, Valeriv
    Givens, Naomi
    de Oliveira, Carlos Fernando
    Brennan, Clare
    LANCET HIV, 2015, 2 (04): : E127 - E136
  • [26] The MONET trial: week 144 analysis of the efficacy of darunavir/ritonavir (DRV/r) monotherapy versus DRV/r plus two nucleoside reverse transcriptase inhibitors, for patients with viral load <50 HIV-1 RNA copies/mL at baseline
    Arribas, J. R.
    Clumeck, N.
    Nelson, M.
    Hill, A.
    van Delft, Y.
    Moecklinghoff, C.
    HIV MEDICINE, 2012, 13 (07) : 398 - 405
  • [27] Week-48 results of AMBER: phase 3, randomised, double-blind trial in antiretroviral treatment (ART)-naive HIV-1-infected adults to evaluate the efficacy and safety of the once-daily, single-tablet regimen (STR) of darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) versus darunavir/cobicistat (DRV/c) plus emtricitabine/tenofovir disoproxil fumarate (FTC/TDF)
    Gallant, J.
    Orkin, C.
    Molina, J-M
    Negredo, E.
    Antinori, A.
    Mills, A.
    Eron, J.
    Reynes, J.
    van Landuyt, E.
    Hufkens, V.
    Jezorwski, J.
    Opsomer, M.
    HIV MEDICINE, 2018, 19 : S32 - S32
  • [28] Clinical and pharmacokinetic data support once-daily low-dose boosted saquinavir (1,200 milligrams saquinavir with 100 milligrams ritonavir) in treatment-naive or limited protease inhibitor-experienced human immunodeficiency virus-infected patients
    Marin-Niebla, Ana
    Lopez-Cortes, Luis Fernando
    Ruiz-Valderas, Rosa
    Viciana, Pompeyo
    Mata, Rosario
    Gutierrez, Alicia
    Pascual, Rosario
    Rodriguez, Magdalena
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2007, 51 (06) : 2035 - 2042
123